Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B

Infection and Immunity

Volumn 69, Issue 6, 2001, Pages 3762-3771

  Moe, G R ^a   Zuno Mitchell, P ^a   Lee, S S ^a   Lucas, A H ^a   Granoff, D M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN G2A; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; PROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERIOLYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC VARIABILITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; STRAIN DIFFERENCE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BACTERIOLYSIS; FEMALE; HUMANS; IMMUNE SERA; MENINGOCOCCAL INFECTIONS; MICE; NEISSERIA MENINGITIDIS; RATS; RATS, WISTAR; SEROTYPING; VIRULENCE;

EID: 0035024481     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.6.3762-3771.2001     Document Type: Article

References (24)

1. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA
2. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b
3. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation
4. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein
5. Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986
6. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers
7. The meningococcus and mechanisms of pathogenicity
8. Meningococcal vaccines: Past, present and future
9. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid
10. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis
11. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread
12. Candidate Neisseria meningitidis NspA vaccine
13. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection
14. Influence of nutrient limitation and low pH on serogroup B Neisseria meningitidis capsular polysaccharide levels: Correlation with virulence for mice
15. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine
16. Differences in surface expression of NspA among Neisseria meningitidis group B strains
17. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine
18. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
19. Antigenic and molecular conservation of the gonococcal NspA protein
20. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine
21. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
22. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter
23. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitidis serogroup B are prerequisites for virulence of meningococci in the infant rat
24. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial